


## 3-Nitro-L-tyrosine-<sup>13</sup>C<sub>6</sub>

<b>Cat. No.:</b>	HY-113248S1
<b>Molecular Formula:</b>	C <sub>3</sub> <sup>13</sup> C <sub>6</sub> H <sub>10</sub> N <sub>2</sub> O <sub>5</sub>
<b>Molecular Weight:</b>	232.14
<b>Target:</b>	Endogenous Metabolite
<b>Pathway:</b>	Metabolic Enzyme/Protease
<b>Storage:</b>	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



### BIOLOGICAL ACTIVITY

<b>Description</b>	3-Nitro-L-tyrosine- <sup>13</sup> C <sub>6</sub> is the <sup>13</sup> C labeled 3-Nitro-L-tyrosine[1]. 3-Nitro-L-tyrosine is a biomarker of nitrogen free radical species modified proteins in systemic autoimmunogenic conditions[2].
<b>In Vitro</b>	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019 Feb;53(2):211-216.
- [2]. Montoliu C, et al. 3-nitro-tyrosine as a peripheral biomarker of minimal hepatic encephalopathy in patients with liver cirrhosis. *Am J Gastroenterol*. 2011 Sep;106(9):1629-37.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA